A Phase 2 interventional study of Niraparib and Dostarlimab in Ovarian Neoplasms, sponsored by Tesaro, Inc.. Terminated at 27 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-09-10.
Sponsored by Tesaro, Inc. (part of GlaxoSmithKline) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies in Ovarian Neoplasms by GlaxoSmithKline — 5 open to participants now, 7 under way, 5 of them phase 3. Ovarian Neoplasms · GlaxoSmithKline.
Among the 31 studies in Ovarian Neoplasms by GlaxoSmithKline, this one is the 19th largest by enrollment of the 30 interventional ones that give a count, is the only one that started in 2019, is one of 15 in phase 2, and was the 24th registered.
3,387 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.
Browse Ovarian Neoplasms studies →5 of the 31 studies in Ovarian Neoplasms by GlaxoSmithKline are open now, in 12 countries. Recruiting first, the newest first:
GlaxoSmithKline · Sites in Argentina, Australia, Canada and 2 more countries
Ages 18+ · Women only
GlaxoSmithKline · Sites in Australia, Canada, Japan and 1 more country
Ages 18+ · Women only
GlaxoSmithKline · Sites in Australia, Canada, Japan and 2 more countries
Ages 18+ · Women only
GlaxoSmithKline · Sites in United States, Austria, Canada and 5 more countries
Ages 18+
GlaxoSmithKline
Ages 18+ · Women only
By country, each count listing its studies:
Of the 602 Ovarian Neoplasms studies recruiting now, 439 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 16 · Phase 3 7 · Phase 4 1
First in 1997; this study’s year is marked. 1 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 41 is below the median of 54 across 2,553 interventional studies indexed under Ovarian Neoplasms.
Median enrollment 77 across the 30 interventional studies. Of the 22 that completed or were terminated, 16 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Tesaro, Inc., one of the names counted as GlaxoSmithKline. Under that name alone:
Tesaro, Inc. is the lead sponsor of 33 studies on the registry; none are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 12 (100%) have results posted.
1 of the studies in Ovarian Neoplasms by GlaxoSmithKline that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04641247GlaxoSmithKlineA Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study | 2026-12-28 |
Add it to your calendar (.ics) → With an account.
Among the 31 studies in Ovarian Neoplasms by GlaxoSmithKline, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is an open-label, single-arm Phase 2 study to evaluate the efficacy and safety of combination of niraparib and dostarlimab (TSR-042) in participants with advanced, relapsed, high-grade ovarian, fallopian tube, endometrioid, clear cell ovarian or primary peritoneal cancer without known breast cancer susceptibility gene (BRCA) mutation who have platinum-resistant disease and who have also been previously treated with bevacizumab.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participant with a known history of (HIV) are allowed if they meet all of the following criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with body weight ≥77 kilogram (kg) and platelet count ≥150,000/microliter (μL) at baseline were administered Niraparib 300 milligram (mg) once daily (QD) and participants with body weight \<77 kg or platelet count \<150,000/μL at baseline were administered Niraparib 200 mg QD. Niraparib was administered continuously until Progressive disease (PD) or toxicity. Dostarlimab (TSR-042) was administered as an intravenous (IV) infusion of 500 mg once every three weeks (Q3W) from Cycle 1 Day 1 through Cycle 4. Beginning at Cycle 5, Dostarlimab (TSR-042) was administered via an IV infusion of 1000 mg on Day 1 of each 6-week cycle until PD or toxicity, up to 27 months.
Drug: Niraparib · Drug: Dostarlimab
Niraparib is a potent, orally active poly (adenosine diphosphate-ribose) polymerase (PARP)-1 and PARP2 inhibitor being developed as a treatment for participants with tumors that harbor defects in the homologous recombination deoxyribonucleic acid (DNA) repair pathway or that are driven by PARP-mediated transcription factors.
Also known as: ZEJULA
TSR-042 is a humanized monoclonal antibody that binds with high affinity to programmed cell death-1 (PD-1) resulting in inhibition of binding to programmed cell-death receptor ligands 1 and 2 (PD-L1 and PD-L2).
Objective Response Rate (ORR) in Participants With Platinum-resistant Ovarian Cancer (PROC)
ORR is defined as the percentage of participants who have achieved confirmed complete response (CR) or partial response (PR), as determined by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) criteria based on Investigator assessment and computed tomography (CT) scans were commonly used for tumor imaging.
Time frame: Up to approximately 22 months
ORR in Participants With PROC Who Have Programmed Cell Death-ligand 1 (PD-L 1) Positive Status
ORR is defined as the percentage of participants who have achieved confirmed CR or PR, as determined by RECIST v1.1 criteria based on Investigator assessment and CT scans were commonly used for tumor imaging. PD-L1 is a ligand that binds to PD-L1 protein on tumor infiltrating T cells and renders the T cells inactive. Any PD-L1 positive tissue sample with combined positive score (vCPS) \>=5% was used as specified cut-point for the assessment of PD-L1 positive patient subset with PROC. vCPS was defined as the percentage of tumor cells and immune cells staining positive within the total tumor area.
Time frame: Up to approximately 22 months
Duration of Response (DOR) in Participants With PROC
DOR is defined as the time from first documentation of response (CR or PR) until the time of first documentation of disease progression or death by any cause in the absence of progression by RECIST v.1.1 based on Investigator assessment.
Time frame: Up to approximately 22 months
DOR in Participants With PROC Who Have PD-L 1 Positive Status
DOR is defined as the time from first documentation of response (CR or PR) until the time of first documentation of disease progression or death by any cause in the absence of progression by RECIST v.1.1 based on Investigator assessment. PD-L1 is a ligand that binds to PD-L1 protein on tumor infiltrating T cells and renders the T cells inactive. Any PD-L1 positive tissue sample with vCPS \>=5% was used as specified cut-point for the assessment of PD-L1 patient subset with PROC. vCPS was defined as the percentage of tumor cells and immune cells staining positive within the total tumor area.
Time frame: Up to approximately 22 months
Progression-free Survival (PFS) in Participants With PROC
PFS is defined as the time from the date of the first dose of study treatment to the earlier date of assessment of progression or death by any cause in the absence of progression by RECIST v.1.1 based on Investigator assessment.
Time frame: Up to approximately 22 months
PFS in Participants With PROC Who Have PD-L 1 Positive Status
PFS is defined as the time from the date of the first dose of study treatment to the earlier date of assessment of progression or death by any cause in the absence of progression by RECIST v.1.1 based on Investigator assessment. PD-L1 is a ligand that binds to PD-L1 protein on tumor infiltrating T cells and renders the T cells inactive. Any PD-L1 positive tissue sample with a vCPS \>=5% was used as specified cut-point for the assessment of PD-L1 positive patient subset with PROC. vCPS was defined as the percentage of tumor cells and immune cells staining positive within the total tumor area.
Time frame: Up to approximately 22 months
Overall Survival (OS) in Participants With PROC
OS is defined as the time from the date of the first dose of study treatment to the date of death by any cause.
Time frame: Up to approximately 22 months
OS in Participants With PROC Who Have PD-L 1 Positive Status
OS is defined as the time from the date of the first dose of study treatment to the date of death by any cause. PD-L1 is a ligand that binds to PD-L1 protein on tumor infiltrating T cells and renders the T cells inactive. Any PD-L1 positive tissue sample with vCPS \>=5% was used as specified cut-point for the assessment of PD-L1 positive patient subset with PROC. vCPS was defined as the percentage of tumor cells and immune cells staining positive within the total tumor area.
Time frame: Up to approximately 22 months
Disease Control Rate (DCR) in Participants With PROC
DCR is defined as the percentage of participants who have achieved best overall response (BOR) of CR, PR, or stable disease (SD) per RECIST v.1.1 based on the investigator's assessment.
Time frame: Up to approximately 22 months
DCR in Participants With PROC Who Have PD-L 1 Positive Status
DCR is defined as the percentage of participants who have achieved BOR of CR, PR, or SD per RECIST v.1.1 based on the investigator's assessment. PD-L1 is a ligand that binds to PD-L1 protein on tumor infiltrating T cells and renders the T cells inactive. Any PD-L1 positive tissue sample with vCPS \>=5% was used as specified cut-point for the assessment of PD-L1 positive patient subset with PROC. vCPS was defined as the percentage of tumor cells and immune cells staining positive within the total tumor area.
Time frame: Up to approximately 22 months
ORR in Participants With PROC Based on Independent Review Committee (IRC) Assessment
ORR is defined as the percentage of participants who have achieved confirmed CR or PR per RECIST v1.1 based on the independent review committee assessment.
Time frame: Up to approximately 22 months
ORR in Participants With PROC Who Have PD-L 1 Positive Status Based on IRC Assessment
ORR is defined as the percentage of participants who have achieved confirmed CR or PR per RECIST v1.1 based on the independent review committee assessment. PD-L1 is a ligand that binds to PD-L1 protein on tumor infiltrating T cells and renders the T cells inactive. Any PD-L1 positive tissue sample with a vCPS \>=5% was used as specified cut-point for the assessment of PD-L1 positive patient subset with PROC. vCPS was defined as the percentage of tumor cells and immune cells staining positive within the total tumor area.
Time frame: Up to approximately 22 months
DOR in Participants With PROC Based on IRC Assessment
DOR is defined as the time from first documentation of response (CR or PR) until the time of first documentation of disease progression or death by any cause in the absence of progression by RECIST v.1.1 based on Independent Review Committee assessment.
Time frame: Up to approximately 22 months
DOR in Participants With PROC Who Have PD-L 1 Positive Status Based on IRC Assessment
DOR is defined as the time from first documentation of response (CR or PR) until the time of first documentation of disease progression or death by any cause in the absence of progression by RECIST v.1.1 based on Independent Review Committee assessment. PD-L1 is a ligand that binds to PD-L1 protein on tumor infiltrating T cells and renders the T cells inactive. Any PD-L1 positive tissue sample with a vCPS \>=5% was used as specified cut-point for the assessment of PD-L1 positive patient subset with PROC. vCPS was defined as the percentage of tumor cells and immune cells staining positive within the total tumor area.
Time frame: Up to approximately 22 months
PFS in Participants With PROC Based on IRC Assessment
PFS is defined as the time from the date of the first dose of study treatment to the earlier date of assessment of progression or death by any cause in the absence of progression by RECIST v.1.1 based on Independent Review Committee Assessment.
Time frame: Up to approximately 22 months
PFS in Participants With PROC Who Have PD-L 1 Positive Status Based on IRC Assessment
PFS is defined as the time from the date of the first dose of study treatment to the earlier date of assessment of progression or death by any cause in the absence of progression by RECIST v.1.1 based on IRC Assessment. PD-L1 is a ligand that binds to PD-L1 protein on tumor infiltrating T cells and renders the T cells inactive. Any PD-L1 positive tissue sample with a vCPS \>=5% was used as specified cut-point for the assessment of PD-L1 positive patient subset with PROC. vCPS was defined as the percentage of tumor cells and immune cells staining positive within the total tumor area.
Time frame: Up to approximately 22 months
DCR in Participants With PROC Based on IRC Assessment
DCR is defined as the percentage of participants who have achieved BOR of CR, PR, or SD per RECIST v.1.1 based on IRC Assessment.
Time frame: Up to approximately 22 months
DCR in Participants With PROC Who Have PD-L 1 Positive Status Based on IRC Assessment
DCR is defined as the percentage of participants who have achieved BOR of CR, PR, or SD per RECIST v.1.1 based on Independent Review Committee Assessment. PD-L1 is a ligand that binds to PD-L1 protein on tumor infiltrating T cells and renders the T cells inactive. Any PD-L1 positive tissue sample with vCPS \>=5% was used as specified cut-point for the assessment of PD-L1 positive patient subset with PROC. vCPS was defined as the percentage of tumor cells and immune cells staining positive within the total tumor area.
Time frame: Up to approximately 22 months
Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Treatment-emergent Adverse Events (TEAEs) and Adverse Event of Special Interest (AESI)
An AE is any untoward medical occurrence in a patient administered with a medicinal product and that does which may or may not have a causal relationship with this treatment. A SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect or any other situation according to medical or scientific judgment. TEAEs are any event that occurred between first dose of study drug up to 22 months, which were absent before treatment or that had worsened relative to pretreatment state. AESI were any AE (serious or non-serious) that is of scientific and medical concern specific to the study treatment, for which ongoing monitoring and rapid communication by the Investigator to the Sponsor was done.
Time frame: Up to approximately 27 months
Number of Participants With Grade Shift From Baseline in Hematology
Blood samples were collected for the analysis of hematology parameters and each parameter was graded according to National Cancer Institute (NCI)-Common Terminology Criteria for Adverse Events (CTCAE) version 4.3. Grade 0: Normal, Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences. Baseline was defined as the most recent measurement prior to the first administration of study treatment. Data has been presented for the number of participants with hematology grade shifts from baseline grade to grade 3 and 4 for each parameter.
Time frame: Up to approximately 27 months
Number of Participants With Grade Shift From Baseline in Plasma Chemistry
Blood samples were collected and the clinical chemistry parameters assessed were Albumin (Alb), alanine aminotransferase (ALT), amylase, aspartate aminotransferase (AST), alkaline phosphatase (ALP), sodium, total bilirubin (TB), creatinine, glucose, magnesium and potassium. The Grade shift post baseline data of each parameter from Grade 0 through Grade 4 was based on the CTCAE version 4.03, grading scale, as per intensity, namely Grade 0: Normal, Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences. Baseline was defined as the most recent measurement prior to the first administration of study treatment. Data has been presented for the number of participants with plasma chemistry grade shifts from baseline grade to grade 3 and 4 for each parameter.
Time frame: Up to approximately 27 months
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)
Baseline was defined as the most recent measurement prior to the first administration of study treatment. The change from baseline was calculated by subtracting the baseline values from the individual post-randomization values. The minimum (min) and maximum (max) change from baseline values have been reported.
Time frame: Up to approximately 27 months
Change From Baseline in Pulse Rate
Baseline was defined as the most recent measurement prior to the first administration of study treatment. The change from baseline was calculated by subtracting the baseline values from the individual post-randomization values. The minimum (min) and maximum (max) change from baseline values have been reported.
Time frame: Up to approximately 27 months
Change From Baseline in Temperature
Baseline was defined as the most recent measurement prior to the first administration of study treatment. The change from baseline was calculated by subtracting the baseline values from the individual post-randomization values. The minimum (min) and maximum (max) change from baseline values have been reported.
Time frame: Up to approximately 27 months
Change From Baseline in Prothrombin International Normalized Ratio
Blood samples were collected to evaluate Prothrombin International Normalized Ratio (INR). Baseline was defined as the most recent measurement prior to the first administration of study treatment. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.
Time frame: Baseline and up to approximately 27 months
Change in Baseline in Activated Partial Thromboplastin Time
Blood samples were planned to be collected to evaluate activated partial thromboplastin time (APTT). Baseline was defined as the most recent measurement prior to the first administration of study treatment. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.
Time frame: Baseline and up to approximately 27 months
Change From Baseline in Thyrotropin
Blood samples were collected to evaluate thyrotropin at indicated time points. Baseline was defined as the most recent measurement prior to the first administration of study treatment. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.
Time frame: Baseline and up to approximately 27 months
From October 2019 until September 2020, 72 participants were screened and 41 participants were enrolled (31 screen failures)
| Milestone | Niraparib+Dostarlimab (TSR-042) |
|---|---|
| Started | 41 |
| Completed | 1 |
| Not completed | 40 |
| Withdrew: Death | 22 |
| Withdrew: Lost to follow-up | 1 |
| Withdrew: Withdrawal by subject | 6 |
| Withdrew: Sponsor decision to terminate study | 11 |
ORR is defined as the percentage of participants who have achieved confirmed complete response (CR) or partial response (PR), as determined by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) criteria based on Investigator assessment and computed tomography (CT) scans were commonly used for tumor imaging.
| Percentage of Participants | Niraparib+Dostarlimab (TSR-042) |
|---|---|
| Objective Response Rate (ORR) in Participants With Platinum-resistant Ovarian Cancer (PROC) | 7.3 (1.5 to 19.9) |
ORR is defined as the percentage of participants who have achieved confirmed CR or PR, as determined by RECIST v1.1 criteria based on Investigator assessment and CT scans were commonly used for tumor imaging. PD-L1 is a ligand that binds to PD-L1 protein on tumor infiltrating T cells and renders the T cells inactive. Any PD-L1 positive tissue sample with combined positive score (vCPS) \>=5% was used as specified cut-point for the assessment of PD-L1 positive patient subset with PROC. vCPS was defined as the percentage of tumor cells and immune cells staining positive within the total tumor area.
| Percentage of Participants | Niraparib+Dostarlimab (TSR-042) |
|---|---|
| ORR in Participants With PROC Who Have Programmed Cell Death-ligand 1 (PD-L 1) Positive Status | 7.7 (0.2 to 36) |
DOR is defined as the time from first documentation of response (CR or PR) until the time of first documentation of disease progression or death by any cause in the absence of progression by RECIST v.1.1 based on Investigator assessment.
| Months | Niraparib+Dostarlimab (TSR-042) |
|---|---|
| Duration of Response (DOR) in Participants With PROC | 3.8 (3 to 9.2) |
DOR is defined as the time from first documentation of response (CR or PR) until the time of first documentation of disease progression or death by any cause in the absence of progression by RECIST v.1.1 based on Investigator assessment. PD-L1 is a ligand that binds to PD-L1 protein on tumor infiltrating T cells and renders the T cells inactive. Any PD-L1 positive tissue sample with vCPS \>=5% was used as specified cut-point for the assessment of PD-L1 patient subset with PROC. vCPS was defined as the percentage of tumor cells and immune cells staining positive within the total tumor area.
| Months | Niraparib+Dostarlimab (TSR-042) |
|---|---|
| DOR in Participants With PROC Who Have PD-L 1 Positive Status | NA (3.8 to NA) |
PFS is defined as the time from the date of the first dose of study treatment to the earlier date of assessment of progression or death by any cause in the absence of progression by RECIST v.1.1 based on Investigator assessment.
| Months | Niraparib+Dostarlimab (TSR-042) |
|---|---|
| Progression-free Survival (PFS) in Participants With PROC | 2.1 (1.97 to 2.23) |
PFS is defined as the time from the date of the first dose of study treatment to the earlier date of assessment of progression or death by any cause in the absence of progression by RECIST v.1.1 based on Investigator assessment. PD-L1 is a ligand that binds to PD-L1 protein on tumor infiltrating T cells and renders the T cells inactive. Any PD-L1 positive tissue sample with a vCPS \>=5% was used as specified cut-point for the assessment of PD-L1 positive patient subset with PROC. vCPS was defined as the percentage of tumor cells and immune cells staining positive within the total tumor area.
| Months | Niraparib+Dostarlimab (TSR-042) |
|---|---|
| PFS in Participants With PROC Who Have PD-L 1 Positive Status | 2.22 (1.64 to NA) |
OS is defined as the time from the date of the first dose of study treatment to the date of death by any cause.
| Months | Niraparib+Dostarlimab (TSR-042) |
|---|---|
| Overall Survival (OS) in Participants With PROC | 10.61 (7.26 to 13.44) |
OS is defined as the time from the date of the first dose of study treatment to the date of death by any cause. PD-L1 is a ligand that binds to PD-L1 protein on tumor infiltrating T cells and renders the T cells inactive. Any PD-L1 positive tissue sample with vCPS \>=5% was used as specified cut-point for the assessment of PD-L1 positive patient subset with PROC. vCPS was defined as the percentage of tumor cells and immune cells staining positive within the total tumor area.
| Months | Niraparib+Dostarlimab (TSR-042) |
|---|---|
| OS in Participants With PROC Who Have PD-L 1 Positive Status | NA (7.26 to NA) |
DCR is defined as the percentage of participants who have achieved best overall response (BOR) of CR, PR, or stable disease (SD) per RECIST v.1.1 based on the investigator's assessment.
| Percentage of Participants | Niraparib+Dostarlimab (TSR-042) |
|---|---|
| Disease Control Rate (DCR) in Participants With PROC | 29.3 (16.1 to 45.5) |
DCR is defined as the percentage of participants who have achieved BOR of CR, PR, or SD per RECIST v.1.1 based on the investigator's assessment. PD-L1 is a ligand that binds to PD-L1 protein on tumor infiltrating T cells and renders the T cells inactive. Any PD-L1 positive tissue sample with vCPS \>=5% was used as specified cut-point for the assessment of PD-L1 positive patient subset with PROC. vCPS was defined as the percentage of tumor cells and immune cells staining positive within the total tumor area.
| Percentage of Participants | Niraparib+Dostarlimab (TSR-042) |
|---|---|
| DCR in Participants With PROC Who Have PD-L 1 Positive Status | 38.5 (13.9 to 68.4) |
ORR is defined as the percentage of participants who have achieved confirmed CR or PR per RECIST v1.1 based on the independent review committee assessment.
No measurements were reported for this outcome.
ORR is defined as the percentage of participants who have achieved confirmed CR or PR per RECIST v1.1 based on the independent review committee assessment. PD-L1 is a ligand that binds to PD-L1 protein on tumor infiltrating T cells and renders the T cells inactive. Any PD-L1 positive tissue sample with a vCPS \>=5% was used as specified cut-point for the assessment of PD-L1 positive patient subset with PROC. vCPS was defined as the percentage of tumor cells and immune cells staining positive within the total tumor area.
No measurements were reported for this outcome.
DOR is defined as the time from first documentation of response (CR or PR) until the time of first documentation of disease progression or death by any cause in the absence of progression by RECIST v.1.1 based on Independent Review Committee assessment.
No measurements were reported for this outcome.
DOR is defined as the time from first documentation of response (CR or PR) until the time of first documentation of disease progression or death by any cause in the absence of progression by RECIST v.1.1 based on Independent Review Committee assessment. PD-L1 is a ligand that binds to PD-L1 protein on tumor infiltrating T cells and renders the T cells inactive. Any PD-L1 positive tissue sample with a vCPS \>=5% was used as specified cut-point for the assessment of PD-L1 positive patient subset with PROC. vCPS was defined as the percentage of tumor cells and immune cells staining positive within the total tumor area.
No measurements were reported for this outcome.
PFS is defined as the time from the date of the first dose of study treatment to the earlier date of assessment of progression or death by any cause in the absence of progression by RECIST v.1.1 based on Independent Review Committee Assessment.
No measurements were reported for this outcome.
PFS is defined as the time from the date of the first dose of study treatment to the earlier date of assessment of progression or death by any cause in the absence of progression by RECIST v.1.1 based on IRC Assessment. PD-L1 is a ligand that binds to PD-L1 protein on tumor infiltrating T cells and renders the T cells inactive. Any PD-L1 positive tissue sample with a vCPS \>=5% was used as specified cut-point for the assessment of PD-L1 positive patient subset with PROC. vCPS was defined as the percentage of tumor cells and immune cells staining positive within the total tumor area.
No measurements were reported for this outcome.
DCR is defined as the percentage of participants who have achieved BOR of CR, PR, or SD per RECIST v.1.1 based on IRC Assessment.
No measurements were reported for this outcome.
DCR is defined as the percentage of participants who have achieved BOR of CR, PR, or SD per RECIST v.1.1 based on Independent Review Committee Assessment. PD-L1 is a ligand that binds to PD-L1 protein on tumor infiltrating T cells and renders the T cells inactive. Any PD-L1 positive tissue sample with vCPS \>=5% was used as specified cut-point for the assessment of PD-L1 positive patient subset with PROC. vCPS was defined as the percentage of tumor cells and immune cells staining positive within the total tumor area.
No measurements were reported for this outcome.
An AE is any untoward medical occurrence in a patient administered with a medicinal product and that does which may or may not have a causal relationship with this treatment. A SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect or any other situation according to medical or scientific judgment. TEAEs are any event that occurred between first dose of study drug up to 22 months, which were absent before treatment or that had worsened relative to pretreatment state. AESI were any AE (serious or non-serious) that is of scientific and medical concern specific to the study treatment, for which ongoing monitoring and rapid communication by the Investigator to the Sponsor was done.
| Participants | Niraparib+Dostarlimab (TSR-042) |
|---|---|
| AEs | 41 |
| SAEs | 23 |
| TEAE | 41 |
| AESIs | 2 |
Blood samples were collected for the analysis of hematology parameters and each parameter was graded according to National Cancer Institute (NCI)-Common Terminology Criteria for Adverse Events (CTCAE) version 4.3. Grade 0: Normal, Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences. Baseline was defined as the most recent measurement prior to the first administration of study treatment. Data has been presented for the number of participants with hematology grade shifts from baseline grade to grade 3 and 4 for each parameter.
| Participants | Niraparib+Dostarlimab (TSR-042) |
|---|---|
| Hemoglobin, Grade 0 to Grade 3 | 3 |
| Hemoglobin, Grade 1 to Grade 3 | 5 |
| Hemoglobin, Grade 2 to Grade 3 | 1 |
| Hemoglobin, Grade 3 to Grade 3 | 0 |
| Hemoglobin, Grade 4 to Grade 3 | 0 |
| Hemoglobin, Grade 0 to Grade 4 | 0 |
| Hemoglobin, Grade 1 to Grade 4 | 0 |
| Hemoglobin, Grade 2 to Grade 4 | 0 |
| Hemoglobin, Grade 3 to Grade 4 | 0 |
| Hemoglobin, Grade 4 to Grade 4 | 0 |
| Leukocytes, Grade 0 to Grade 3 | 0 |
| Leukocytes, Grade 1 to Grade 3 | 0 |
| Leukocytes, Grade 2 to Grade 3 | 0 |
| Leukocytes, Grade 3 to Grade 3 | 0 |
| Leukocytes, Grade 4 to Grade 3 | 0 |
| Leukocytes, Grade 0 to Grade 4 | 0 |
| Leukocytes, Grade 1 to Grade 4 | 0 |
| Leukocytes, Grade 2 to Grade 4 | 0 |
| Leukocytes, Grade 3 to Grade 4 | 0 |
| Leukocytes, Grade 4 to Grade 4 | 0 |
| Lymphocytes, Grade 0 to Grade 3 | 5 |
| Lymphocytes, Grade 1 to Grade 3 | 3 |
| Lymphocytes, Grade 2 to Grade 3 | 3 |
| Lymphocytes, Grade 3 to Grade 3 | 0 |
| Lymphocytes, Grade 4 to Grade 3 | 0 |
| Lymphocytes, Grade 0 to Grade 4 | 1 |
| Lymphocytes, Grade 1 to Grade 4 | 0 |
| Lymphocytes, Grade 2 to Grade 4 | 0 |
| Lymphocytes, Grade 3 to Grade 4 | 0 |
| Lymphocytes, Grade 4 to Grade 4 | 0 |
| Neutrophil Count, Grade 0 to Grade 3 | 1 |
| Neutrophil Count, Grade 1 to Grade 3 | 0 |
| Neutrophil Count, Grade 2 to Grade 3 | 0 |
| Neutrophil Count, Grade 3 to Grade 3 | 0 |
| Neutrophil Count, Grade 4 to Grade 3 | 0 |
| Neutrophil Count, Grade 0 to Grade 4 | 1 |
| Neutrophil Count, Grade 1 to Grade 4 | 0 |
| Neutrophil Count, Grade 2 to Grade 4 | 0 |
| Neutrophil Count, Grade 3 to Grade 4 | 0 |
| Neutrophil Count, Grade 4 to Grade 4 | 0 |
| Platelets, Grade 0 to Grade 3 | 4 |
| Platelets, Grade 1 to Grade 3 | 1 |
| Platelets, Grade 2 to Grade 3 | 0 |
| Platelets, Grade 3 to Grade 3 | 0 |
| Platelets, Grade 4 to Grade 3 | 0 |
| Platelets, Grade 0 to Grade 4 | 4 |
| Platelets, Grade 1 to Grade 4 | 0 |
| Platelets, Grade 2 to Grade 4 | 0 |
| Platelets, Grade 3 to Grade 4 | 0 |
| Platelets, Grade 4 to Grade 4 | 0 |
Blood samples were collected and the clinical chemistry parameters assessed were Albumin (Alb), alanine aminotransferase (ALT), amylase, aspartate aminotransferase (AST), alkaline phosphatase (ALP), sodium, total bilirubin (TB), creatinine, glucose, magnesium and potassium. The Grade shift post baseline data of each parameter from Grade 0 through Grade 4 was based on the CTCAE version 4.03, grading scale, as per intensity, namely Grade 0: Normal, Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences. Baseline was defined as the most recent measurement prior to the first administration of study treatment. Data has been presented for the number of participants with plasma chemistry grade shifts from baseline grade to grade 3 and 4 for each parameter.
| Participants | Niraparib+Dostarlimab (TSR-042) |
|---|---|
| ALT, Grade 0 to Grade 3 | 3 |
| ALT, Grade 1 to Grade 3 | 0 |
| ALT, Grade 2 to Grade 3 | 0 |
| ALT, Grade 3 to Grade 3 | 0 |
| ALT, Grade 4 to Grade 3 | 0 |
| ALT, Grade 0 to Grade 4 | 1 |
| ALT, Grade 1 to Grade 4 | 0 |
| ALT, Grade 2 to Grade 4 | 0 |
| ALT, Grade 3 to Grade 4 | 0 |
| ALT, Grade 4 to Grade 4 | 0 |
| Alb, Grade 0 to Grade 3 | 1 |
| Alb, Grade 1 to Grade 3 | 0 |
| Alb, Grade 2 to Grade 3 | 0 |
| Alb, Grade 3 to Grade 3 | 0 |
| Alb, Grade 4 to Grade 3 | 0 |
| Alb, Grade 0 to Grade 4 | 0 |
| Alb, Grade 1 to Grade 4 | 0 |
| Alb, Grade 2 to Grade 4 | 0 |
| Alb, Grade 3 to Grade 4 | 0 |
| Alb, Grade 4 to Grade 4 | 0 |
| ALP, Grade 0 to Grade 3 | 3 |
| ALP, Grade 1 to Grade 3 | 1 |
| ALP, Grade 2 to Grade 3 | 1 |
| ALP, Grade 3 to Grade 3 | 0 |
| ALP, Grade 4 to Grade 3 | 0 |
| ALP, Grade 0 to Grade 4 | 0 |
| ALP, Grade 1 to Grade 4 | 1 |
| ALP, Grade 2 to Grade 4 | 0 |
| ALP, Grade 3 to Grade 4 | 0 |
| ALP, Grade 4 to Grade 4 | 0 |
| Amylase, Grade 0 to Grade 3 | 0 |
| Amylase, Grade 1 to Grade 3 | 0 |
| Amylase, Grade 2 to Grade 3 | 0 |
| Amylase, Grade 3 to Grade 3 | 0 |
| Amylase, Grade 4 to Grade 3 | 0 |
| Amylase, Grade 0 to Grade 4 | 0 |
| Amylase, Grade 1 to Grade 4 | 0 |
| Amylase, Grade 2 to Grade 4 | 0 |
| Amylase, Grade 3 to Grade 4 | 0 |
| Amylase, Grade 4 to Grade 4 | 0 |
| AST, Grade 0 to Grade 3 | 4 |
| AST, Grade 1 to Grade 3 | 1 |
| AST, Grade 2 to Grade 3 | 0 |
| AST, Grade 3 to Grade 3 | 0 |
| AST, Grade 4 to Grade 3 | 0 |
| AST, Grade 0 to Grade 4 | 0 |
| AST, Grade 1 to Grade 4 | 0 |
| AST, Grade 2 to Grade 4 | 0 |
| AST, Grade 3 to Grade 4 | 0 |
| AST, Grade 4 to Grade 4 | 0 |
| TB, Grade 0 to Grade 3 | 1 |
| TB, Grade 1 to Grade 3 | 0 |
| TB, Grade 2 to Grade 3 | 0 |
| TB, Grade 3 to Grade 3 | 0 |
| TB, Grade 4 to Grade 3 | 0 |
| TB, Grade 0 to Grade 4 | 1 |
| TB, Grade 1 to Grade 4 | 0 |
| TB, Grade 2 to Grade 4 | 0 |
| TB, Grade 3 to Grade 4 | 0 |
| TB, Grade 4 to Grade 4 | 0 |
| Creatinine, Grade 0 to Grade 3 | 1 |
| Creatinine, Grade 1 to Grade 3 | 0 |
| Creatinine, Grade 2 to Grade 3 | 0 |
| Creatinine, Grade 3 to Grade 3 | 0 |
| Creatinine, Grade 4 to Grade 3 | 0 |
| Creatinine, Grade 0 to Grade 4 | 0 |
| Creatinine, Grade 1 to Grade 4 | 0 |
| Creatinine, Grade 2 to Grade 4 | 0 |
| Creatinine, Grade 3 to Grade 4 | 0 |
| Creatinine, Grade 4 to Grade 4 | 0 |
| Glucose high, Grade 0 to Grade 3 | 0 |
| Glucose high, Grade 1 to Grade 3 | 3 |
| Glucose high, Grade 2 to Grade 3 | 0 |
| Glucose high, Grade 3 to Grade 3 | 1 |
| Glucose high, Grade 4 to Grade 3 | 0 |
| Glucose high, Grade 0 to Grade 4 | 0 |
| Glucose high, Grade 1 to Grade 4 | 0 |
| Glucose high, Grade 2 to Grade 4 | 0 |
| Glucose high, Grade 3 to Grade 4 | 0 |
| Glucose high, Grade 4 to Grade 4 | 0 |
| Glucose low, Grade 0 to Grade 3 | 0 |
| Glucose low, Grade 1 to Grade 3 | 0 |
| Glucose low, Grade 2 to Grade 3 | 0 |
| Glucose low, Grade 3 to Grade 3 | 0 |
| Glucose low, Grade 4 to Grade 3 | 0 |
| Glucose low, Grade 0 to Grade 4 | 0 |
| Glucose low, Grade 1 to Grade 4 | 0 |
| Glucose low, Grade 2 to Grade 4 | 0 |
| Glucose low, Grade 3 to Grade 4 | 0 |
| Glucose low, Grade 4 to Grade 4 | 0 |
| Magnesium high, Grade 0 to Grade 3 | 1 |
| Magnesium high, Grade 1 to Grade 3 | 0 |
| Magnesium high, Grade 2 to Grade 3 | 0 |
| Magnesium high, Grade 3 to Grade 3 | 0 |
| Magnesium high, Grade 4 to Grade 3 | 0 |
| Magnesium high, Grade 0 to Grade 4 | 0 |
| Magnesium high, Grade 1 to Grade 4 | 0 |
| Magnesium high, Grade 2 to Grade 4 | 0 |
| Magnesium high, Grade 3 to Grade 4 | 0 |
| Magnesium high, Grade 4 to Grade 4 | 0 |
| Magnesium low, Grade 0 to Grade 3 | 0 |
| Magnesium low, Grade 1 to Grade 3 | 0 |
| Magnesium low, Grade 2 to Grade 3 | 0 |
| Magnesium low, Grade 3 to Grade 3 | 1 |
| Magnesium low, Grade 4 to Grade 3 | 0 |
| Magnesium low, Grade 0 to Grade 4 | 0 |
| Magnesium low, Grade 1 to Grade 4 | 0 |
| Magnesium low, Grade 2 to Grade 4 | 0 |
| Magnesium low, Grade 3 to Grade 4 | 0 |
| Magnesium low, Grade 4 to Grade 4 | 0 |
| Potassium high, Grade 0 to Grade 3 | 0 |
| Potassium high, Grade 1 to Grade 3 | 0 |
| Potassium high, Grade 2 to Grade 3 | 0 |
| Potassium high, Grade 3 to Grade 3 | 0 |
| Potassium high, Grade 4 to Grade 3 | 0 |
| Potassium high, Grade 0 to Grade 4 | 0 |
| Potassium high, Grade 1 to Grade 4 | 0 |
| Potassium high, Grade 2 to Grade 4 | 0 |
| Potassium high, Grade 3 to Grade 4 | 0 |
| Potassium high, Grade 4 to Grade 4 | 0 |
| Potassium low, Grade 0 to Grade 3 | 3 |
| Potassium low, Grade 1 to Grade 3 | 1 |
| Potassium low, Grade 2 to Grade 3 | 0 |
| Potassium low, Grade 3 to Grade 3 | 0 |
| Potassium low, Grade 4 to Grade 3 | 0 |
| Potassium low, Grade 0 to Grade 4 | 0 |
| Potassium low, Grade 1 to Grade 4 | 0 |
| Potassium low, Grade 2 to Grade 4 | 0 |
| Potassium low, Grade 3 to Grade 4 | 0 |
| Potassium low, Grade 4 to Grade 4 | 0 |
| Sodium high, Grade 0 to Grade 3 | 0 |
| Sodium high, Grade 1 to Grade 3 | 0 |
| Sodium high, Grade 2 to Grade 3 | 0 |
| Sodium high, Grade 3 to Grade 3 | 0 |
| Sodium high, Grade 4 to Grade 3 | 0 |
| Sodium high, Grade 0 to Grade 4 | 0 |
| Sodium high, Grade 1 to Grade 4 | 0 |
| Sodium high, Grade 2 to Grade 4 | 0 |
| Sodium high, Grade 3 to Grade 4 | 0 |
| Sodium high, Grade 4 to Grade 4 | 0 |
| Sodium low, Grade 0 to Grade 3 | 4 |
| Sodium low, Grade 1 to Grade 3 | 7 |
| Sodium low, Grade 2 to Grade 3 | 0 |
| Sodium low, Grade 3 to Grade 3 | 0 |
| Sodium low, Grade 4 to Grade 3 | 0 |
| Sodium low, Grade 0 to Grade 4 | 0 |
| Sodium low, Grade 1 to Grade 4 | 0 |
| Sodium low, Grade 2 to Grade 4 | 0 |
| Sodium low, Grade 3 to Grade 4 | 0 |
| Sodium low, Grade 4 to Grade 4 | 0 |
Baseline was defined as the most recent measurement prior to the first administration of study treatment. The change from baseline was calculated by subtracting the baseline values from the individual post-randomization values. The minimum (min) and maximum (max) change from baseline values have been reported.
| Millimeters of mercury | Niraparib+Dostarlimab (TSR-042) |
|---|---|
| DBP, max change post baseline | 10.6 ± 10.07 |
| DBP, min change post baseline | -5.8 ± 11.87 |
| SBP, max change post baseline | 16.5 ± 23.01 |
| SBP, min change post baseline | -12.5 ± 24.61 |
Baseline was defined as the most recent measurement prior to the first administration of study treatment. The change from baseline was calculated by subtracting the baseline values from the individual post-randomization values. The minimum (min) and maximum (max) change from baseline values have been reported.
| Beats per minute | Niraparib+Dostarlimab (TSR-042) |
|---|---|
| max change post baseline | 20.5 ± 14.71 |
| min change post baseline | 1 ± 13.77 |
Baseline was defined as the most recent measurement prior to the first administration of study treatment. The change from baseline was calculated by subtracting the baseline values from the individual post-randomization values. The minimum (min) and maximum (max) change from baseline values have been reported.
| Degrees Celsius | Niraparib+Dostarlimab (TSR-042) |
|---|---|
| max change post baseline | 0.31 ± 0.421 |
| min change post baseline | -0.35 ± 0.422 |
Blood samples were collected to evaluate Prothrombin International Normalized Ratio (INR). Baseline was defined as the most recent measurement prior to the first administration of study treatment. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.
| Ratio | Niraparib+Dostarlimab (TSR-042) |
|---|---|
| Day 2 | 0.2 |
| Day 41 | 0.3 |
| Day 52 | 0.7 |
Blood samples were planned to be collected to evaluate activated partial thromboplastin time (APTT). Baseline was defined as the most recent measurement prior to the first administration of study treatment. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.
| Second | Niraparib+Dostarlimab (TSR-042) |
|---|---|
| Day 2 | 1 |
| Day 41 | 16.9 |
Blood samples were collected to evaluate thyrotropin at indicated time points. Baseline was defined as the most recent measurement prior to the first administration of study treatment. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.
| Milliunits per liter (mU/L) | Niraparib+Dostarlimab (TSR-042) |
|---|---|
| Cycle 5 Day 1 | 8.074 ± 19.737 |
| Cycle 7 Day 1 | 12.79 ± 23.240 |
| Cycle 9 Day 1 | 2.596 |
| Cycle 11 Day 1 | 2.517 |
Collected over All cause mortality, non-SAEs and SAEs were collected from Day 1 up to approximately 27 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Niraparib+Dostarlimab (TSR-042) | 22/41 (53.7%) | 23/41 (56.1%) | 41/41 (100%) |
| Event | Niraparib+Dostarlimab (TSR-042) |
|---|---|
| ThrombocytopeniaBlood and lymphatic system disorders | 3/41 |
| Small intestinal obstructionGastrointestinal disorders | 3/41 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 3/41 |
| AnaemiaBlood and lymphatic system disorders | 2/41 |
| Intestinal obstructionGastrointestinal disorders | 2/41 |
| VomitingGastrointestinal disorders | 2/41 |
| Blood bilirubin increasedInvestigations | 2/41 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 2/41 |
| TachycardiaCardiac disorders | 1/41 |
| Abdominal painGastrointestinal disorders | 1/41 |
| Event | Niraparib+Dostarlimab (TSR-042) |
|---|---|
| NauseaGastrointestinal disorders | 24/41 |
| VomitingGastrointestinal disorders | 19/41 |
| AnaemiaBlood and lymphatic system disorders | 18/41 |
| FatigueGeneral disorders | 18/41 |
| Abdominal painGastrointestinal disorders | 15/41 |
| ConstipationGastrointestinal disorders | 15/41 |
| DiarrhoeaGastrointestinal disorders | 11/41 |
| Platelet count decreasedInvestigations | 11/41 |
| Blood creatinine increasedInvestigations | 10/41 |
| Blood alkaline phosphatase increasedInvestigations | 10/41 |
| Age, Continuous(YEARS) | Niraparib+Dostarlimab (TSR-042) |
|---|---|
| Mean | 62.9 ± 10.59 |
| Sex: Female, Male(Participants) | Niraparib+Dostarlimab (TSR-042) |
|---|---|
| Female | 41 |
| Male | 0 |
| Race/Ethnicity, Customized(Participants) | Niraparib+Dostarlimab (TSR-042) |
|---|---|
| American Indian or Alaska Native | 1 |
| Asian | 2 |
| Black or African American | 3 |
| Unknown | 3 |
| White | 32 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Oct 2019 to primary completion in Aug 2021, 22 months.
Results were first posted in Sep 2022, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dostarlimab